Implementing Health Technology Assessment in Oman

By João L. Carapinha

May 6, 2025

A recent article titled “A roadmap towards implementing health technology assessment in Oman” outlines a strategy for integrating health technology assessment in Oman into the healthcare system over the next decade. This initiative aims to improve resource allocation and facilitate evidence-based decision-making for health technologies.

Strategic Roadmap for HTA Implementation

Oman is developing a phased plan for health technology assessment (HTA) to tackle rising healthcare costs and new medical technologies. The roadmap features short-term capacity building (1-2 years), medium-term expansion of HTA infrastructure (3-5 years), and long-term comprehensive integration (6-10 years). All these phases aim to create a sustainable, evidence-based healthcare system. For a detailed insight into the HTA approach, refer to the original article here.

Current Status and Future Strategy

The Omani HTA system is in its nascent stages but holds significant potential for growth. A thorough gap analysis comparing the current state with the desired future of HTA shaped the implementation roadmap. This approach uniquely suits the strategy to the Omani healthcare context.

A notable aspect of Oman’s strategy is the establishment of a single centralized HTA unit under the Ministry of Health. This approach contrasts with other Middle Eastern countries that usually have multiple HTA bodies, reflecting strong political commitment.

Phased Approach to Implementation

The roadmap delineates a structured three-phase plan:

Short-term (1-2 years):

  • Capacity-building initiatives through targeted training programs
  • Initial HTA infrastructure focusing on pharmaceuticals with significant budget impact
  • Implementing a preliminary cost-effectiveness threshold based on 1-3× GDP per capita

Medium-term (3-5 years):

  • An expanded HTA unit with a broadened focus on medical devices and surgical interventions
  • Creation of cost-effectiveness thresholds specific to Oman
  • Increased public engagement and awareness regarding HTA

Long-term (6-10 years):

  • Expanding the technology focus to include prevention programs and public health initiatives
  • Publishing comprehensive HTA recommendations and appraisal reports
  • Setting transparent timelines for review activities
  • Revising previous policy decisions based on new evaluations

Aligning HTA with National Vision

The incorporation of HTA in Oman resonates with the broader goals of “Oman Vision 2040.” This vision aspires to create a transparent healthcare system that promotes equity and delivers high-quality services. It emphasizes sustainable funding for health initiatives and encourages leadership in scientific research.

In parallel, the European Union is advancing HTA implementations, with new regulations enacted in January 2025. These regulations aim to transform the evaluation of medicines and health technologies.

Similar challenges in HTA implementation are evident globally. A review by the World Health Organization underscores that effective HTA requires robust political commitment, ongoing funding, and integration with health information systems. Oman’s current e-health strategy lays a solid foundation for gathering patient data essential for HTA activities. However, adjustments will be necessary to fully meet HTA requirements.

Economic Implications and Outcomes Research

Enhancing Economic Efficiency

The rollout of HTA in Oman is poised to enhance efficiency in healthcare spending. Presently, about 5.3% of GDP is allocated to healthcare. HTA will optimize resource allocation amid projected increases in healthcare expenditures. The roadmap’s initial focus on high-budget pharmaceuticals exemplifies a prudent strategy.

Transforming Market Access and Reimbursement

The introduction of HTA will alter the processes for health technologies gaining market access in Oman. Manufacturers will be required to:

  • Create evidence packages aligning with Omani standards
  • Adapt to new submission criteria and timelines
  • Engage in potential price negotiations tied to cost-effectiveness evaluations

The establishment of multiple cost-effectiveness thresholds will facilitate more organized reimbursement decisions. Including multi-criteria decision analysis (MCDA) allows for evaluating factors beyond cost-effectiveness.

Regional Collaboration and Influence

As Oman advances this roadmap, it may serve as a model for HTA development in the Gulf Cooperation Council (GCC) region. The study discusses plans for collaborative efforts via the GCC and Gulf Health Council.

Ultimately, the success of Oman’s centralized HTA model could inspire other countries with similar healthcare frameworks.

This roadmap marks a pivotal shift towards evidence-based healthcare decision-making in Oman. By recognizing implementation challenges while establishing clear milestones, Oman is poised for significant advancement in healthcare delivery.

Reference url

Recent Posts

Evolving Burden of Obesity in the US: Key Insights on Obesity Prevention Strategies

By HEOR Staff Writer

October 10, 2025

What are the most effective obesity prevention strategies for reducing long-term healthcare and societal costs in the United States? Recent advanced population models reveal that focusing on early, targeted obesity prevention strategies offers far greater value to health systems and society than ...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications

By João L. Carapinha

October 6, 2025

The U.S. Food and Drug Administration (FDA) has recently approved lurbinectedin SCLC therapy in combination with atezolizumab, or with atezolizumab and hyaluronidase-qvfc, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This regulatory decision reflects ...